Mainstay therapies for type 2 diabetes all attempt to decrease hyperglycaemia by modifying glucose metabolism. The new sodium–glucose co-transporter 2 (SGLT2) inhibitors ('flozins') offer a different approach — increasing renal excretion of glucose.
The new SGLT-2 inhibitors have been PBS listed as dual oral therapy in combination with either metformin or a sulfonylurea in people with type 2 diabetes not controlled by metformin and a sulfonylurea.
This fixed-dose combination has been PBS listed for patients with frequent episodes of asthma while using corticosteroids and who need a long-acting beta-2 agonist added.
This PBS-listed, triple fixed-dose combination antihypertensive is for people not well controlled on a combination of the individual components.
Ivabradine selectively inhibits the sino-atrial ‘pacemaker’ current, leading to heart rate reduction, and has been PBS listed as an add-on option for people on optimal therapy for CHF.
This pressurised metered-dose inhaler (pMDI) presentation of the fixed-dose combination budesonide/eformoterol has been PBS listed for treatment of asthma and COPD.
This composite pack has been PBS listed for treatment of hypercholesterolaemia, in combination with dietary therapy and exercise, in people with elevated cholesterol despite use of a statin and with one or more specified concomitant conditions.
The PBS listing of this anti-resorptive agent has been extended to include the treatment of men with established osteoporosis who are 70 years or older with a BMD T-score of –2.5 or less.
This dipeptidyl peptidase-4 (DPP-4) inhibitor joins the other gliptins already on the PBS as an option for dual oral therapy in combination with either metformin or a sulfonylurea for people with type 2 diabetes not adequately controlled with either drug alone.